介入治疗在原发性肝癌中的应用
2015-03-11辛晟梁
辛晟梁
[摘要] 原发性肝癌在我国属于高发病率、高死亡率的恶性肿瘤,由于其早期症状不突出且无特异性,因此一旦发病,预后很差。原发性肝癌具有特殊的血供方式,1978年日本Yamada教授首次提出了经导管动脉化疗栓塞治疗肝脏肿瘤的设想并实践成功,至此介入治疗成为原发性肝癌的又一种治疗方法。随着新思想、新技术、新材料的不断涌现,介入治疗的优势越来越明显,逐渐成为治疗原发性肝癌的主要方法,甚至是常规方法之一。
[关键词] 原发性肝癌;介入治疗;经导管动脉化疗栓塞
[中图分类号] R735.7 [文献标识码] A [文章编号] 1674-4721(2015)01(b)-0010-05
Application of interventional therapy in primary hepatocellular carcinoma
XIN Sheng-liang
The Second Clinical Medical College of Shanxi Medical University,Taiyuan 030001,China
[Abstract] Primary hepatocellular carcinoma(PHC) is the tumor with high incidence and mortality in our country.For absence of characteristic and differential manifestations in early stage,the prognoses always indicate pessimistic outcomes unexpected once patients feel sick.Primary hepatocellular carcinoma has a special blood supply,in 1978,Japanese professor Yamada first initiated one idea called transcatheter arterial chemoembolization(TACE) which is based on the spcial perfusion of PHC and performed it successfully.From then on,TACE becomes another effective choice to patients with PHC.With new thoughts,new technologies,new materials arising,interventional therapy plays significant roles in such field increasingly.Now,interventional therapy has been a principal treatment to PHC,even employed regularly.
[Key words] Primary hepatocellular carcinoma;Interventional therapy;Transcatheter arterial chemoembolization
原发性肝癌(primary hepatocellular carcinoma,PHC)是世界上最常见的六大恶性肿瘤之一,同时其致死率高居恶性肿瘤的第三位[1]。世界上每年大约有70万人死于原发性肝癌,男性发病率往往会更高,男女患者比例可达2∶1,甚至是4∶1[2]。我国原发性肝癌患者及死亡人数均占全球的50%以上[3]。目前为止,外科手术依然是原发性肝癌的首选治疗方法[2]。然而,我国的原发性肝癌有其自身特点,即起病隐匿、发展迅速,且多数具有肝炎-肝硬化背景,患者一旦出现较为明显的临床症状则往往提示病情已经进展至中、晚期,失去了宝贵的手术机会。
介入放射学(interventional radiology)是在影像设备的引导下,利用经皮穿刺或体表自然孔道路径,引入导管、导丝、球囊导管、支架等相关器材对疾病进行微创诊断与治疗的新型亚学科,其中经导管动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)是介入治疗的突出代表,原发性肝癌则是各种介入治疗手段应用最广、技术最成熟且疗效最确切的恶性肿瘤[4]。……
